USPTO Examiner SINGH ANOOP KUMAR - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18660825TRANSGENIC CORYMay 2024May 2025Abandon1321YesNo
18413219MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENEJanuary 2024April 2025Allow1511YesNo
18526758METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023December 2024Allow1310YesNo
18526745METHODS FOR TARGETED INSERTION OF DNA IN GENESDecember 2023April 2024Allow410YesNo
18363453CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORSAugust 2023March 2025Allow1910YesNo
18347487CHIMERIC ANTIGEN RECEPTOR COMPRISING BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAINJuly 2023August 2024Allow1312YesNo
18325321IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHMay 2023January 2025Abandon2010NoNo
18134095ANTI-VEGF ANTIBODY CONSTRUCTSApril 2023June 2025Allow2641YesNo
18166813Animal Models and Therapeutic MoleculesFebruary 2023June 2025Abandon2810NoNo
17982209METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITIONNovember 2022February 2025Abandon2801NoNo
18047014HUMANIZED IL-15 ANIMALSOctober 2022March 2025Allow2911YesNo
17934981IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHSeptember 2022May 2024Abandon1920NoNo
17929495METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS, AND TRANSDIFFERENTIATION AGENTSeptember 2022December 2024Abandon2710NoNo
17855379Lineage Reprogramming to Induced Cardiac Progenitor Cells (iCPC) By Defined FactorsJune 2022June 2025Allow3520YesNo
17810029MOUSE COMPRISING A HUMANIZED TRKB LOCUSJune 2022April 2025Allow3411YesNo
17837821ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHYJune 2022January 2025Abandon3101NoNo
17830011METHODS FOR TARGETED INSERTION OF DNA IN GENESJune 2022June 2024Allow2410YesNo
17746181IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHMay 2022June 2024Abandon2510NoNo
17740026PARTHENOGENIC ACTIVATION OF HUMAN OOCYTES FOR THE PRODUCTION OF HUMAN EMBRYONIC STEM CELLSMay 2022June 2024Abandon2510NoNo
17770728GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMAN OR CHIMERIC THPOApril 2022June 2025Abandon3801NoNo
17697099AAV-MEDIATED DELIVERY OF ANTIBODIES TO THE INNER EARMarch 2022March 2024Allow2441YesNo
17564729METHODS FOR SCREENING HOST CELLS EXPRESSING TARGET PROTEINSDecember 2021January 2025Allow3621YesNo
17532853METHODS OF TREATING LYSOSOMAL STORAGE DISEASESNovember 2021June 2024Abandon3010NoNo
17613368COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSISNovember 2021June 2025Abandon4301NoNo
17611882Targeting Vector, Nucleic Acid Composition, and Method for Constructing Liver-injured Mouse ModelNovember 2021April 2023Abandon1721NoNo
17519823DEFINITIVE ENDODERMNovember 2021February 2024Abandon2710NoNo
17502944REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF DISEASE AND INJURY IN THE NERVOUS SYSTEMOctober 2021May 2025Abandon4320NoYes
17464774MODULATING CELL PROLIFERATION AND PLURIPOTENCYSeptember 2021November 2024Abandon3820YesNo
17463007MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECTAugust 2021March 2024Allow3110YesNo
17392910AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EARAugust 2021April 2023Allow2121YesNo
17371306ATOPIC DERMATITIS MODEL NON-HUMAN ANIMAL AND USE THEREOFJuly 2021April 2025Abandon4521NoNo
17371924GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLSJuly 2021June 2024Abandon3601NoNo
17340752COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATIONJune 2021November 2024Abandon4221NoYes
17341120TARGETED ELIMINATION OF BACTERIAL GENESJune 2021May 2025Abandon4701NoNo
17335727NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOFJune 2021March 2025Allow4521YesNo
17331097IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHMay 2021March 2023Allow2141YesNo
17244302HUMANIZED TRANSGENIC MOUSE MODELApril 2021February 2024Abandon3301NoNo
17236083HUMANIZED DIPEPTIDYL-PEPTIDASE IV (DPP4) ANIMALSApril 2021November 2024Allow4321YesNo
17226611DIFFERENTIATION OF PLURIPOTENT STEM CELLS USING LAMININS LN-511, LN-521 AND LN-221April 2021March 2025Allow4721YesNo
17226125MOUSE HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENEApril 2021March 2024Allow3611YesNo
17217961CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERSMarch 2021August 2024Allow4030YesNo
17264691Compositions for Identification of Membrane Targets for Enhancement of T cell Activity Against CancerJanuary 2021February 2025Allow4921YesNo
17163093ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOFJanuary 2021April 2022Allow1421YesNo
17163038ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOFJanuary 2021November 2022Abandon2231YesNo
17161801MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENEJanuary 2021October 2023Allow3310YesNo
17153636GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSISJanuary 2021August 2024Abandon4320NoNo
17134209METHOD FOR ACTIVATING IMMUNOCYTES IN VITRODecember 2020November 2024Abandon4721NoNo
17119076PRODUCTION OF FERTILE XY FEMALE ANIMALS BY SILENCING OF GENES ON THE Y CHROMOSOMEDecember 2020March 2024Allow3921YesNo
17117157ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAMEDecember 2020March 2025Allow5131YesNo
16951984ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOFNovember 2020September 2021Allow920YesNo
16952002METHOD OF USING ADENO-ASSOCIATED VIRUS WITH VARIANT CAPSIDNovember 2020September 2021Allow1020YesNo
17048492ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOFOctober 2020April 2024Abandon4201NoNo
16981164MOUSE ARTIFICIAL CHROMOSOME VECTOR AND USE THEREOFSeptember 2020June 2025Allow5731YesNo
16977951CELL PREPARATION FOR TREATMENT AND/OR PREVENTION OF ISCHEMIC DISEASE, AND METHOD FOR SCREENING CELL PREPARATIONSeptember 2020November 2024Abandon5121YesNo
16940277GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORMJuly 2020April 2023Abandon3210NoNo
16929042Osteogenic Differentiation of Bone Marrow Stem Cells and Mesenchymal Stem Cells Using a Combination of Growth FactorsJuly 2020February 2024Abandon4310NoNo
16905557Animal Models and Therapeutic MoleculesJune 2020January 2024Abandon4351NoNo
16870365Animal Models and Therapeutic MoleculesMay 2020June 2025Abandon6071NoNo
16870413Animal Models and Therapeutic MoleculesMay 2020December 2023Abandon4451NoNo
16761911NON-HUMAN ANIMAL AND METHOD FOR PRODUCING SAMEMay 2020April 2024Abandon4721NoNo
16846321METHOD FOR PREPARING A LARGE ANIMAL MODEL WITH PERITONEAL CARCINOMATOSISApril 2020August 2023Allow4030YesNo
16650814CHIMERIC MOUSE COMPRISING STABLY TRANSPLANTED BAT CELLSMarch 2020April 2024Allow4921YesYes
16644267Customized Growth Factor Screening System for Cell CultureMarch 2020October 2023Abandon4421NoNo
16775747P21-Activated Kinase Inhibitor Domain Targeted Transgenic MouseJanuary 2020June 2023Abandon4020NoNo
16744810HYDROGEL-BASED IMPLANTABLE DEVICE AND RELATED METHODSJanuary 2020January 2025Abandon6041YesNo
16630589GENE THERAPY FOR TREATMENT OF INFERTILITYJanuary 2020November 2023Abandon4621YesNo
16741513ADAM6 KNOCKIN MICEJanuary 2020December 2024Abandon5941YesNo
16629396FISH EGG PROCESSING APPARATUSJanuary 2020January 2023Abandon3610NoNo
16732400HUMANIZED IL-15 ANIMALSJanuary 2020July 2022Allow3010YesNo
16731585MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLSDecember 2019June 2023Abandon4241YesYes
16626059SINGLE LUNG CELL-DERIVED ORGANOIDSDecember 2019September 2023Abandon4521NoNo
16715293STEM CELL DELIVERED ONCOLYTIC HERPES SIMPLEX VIRUS AND METHODS FOR TREATING BRAIN TUMORSDecember 2019August 2023Abandon4420NoYes
16704740DNA SEQUENCE THAT INCREASES ODORANT RECEPTOR REPRESENTATION IN THE OLFACTORY SYSTEMDecember 2019April 2024Allow5221YesNo
16691822GENE THERAPY FOR TREATING HEMOPHILIA ANovember 2019October 2020Allow1120YesNo
16612450NSG MICE LACKING MHC CLASS I AND CLASS IINovember 2019May 2023Allow4221YesNo
16678990Generation of Inner Ear CellsNovember 2019August 2022Allow3420YesNo
16601144METHODS FOR TARGETED INSERTION OF DNA IN GENESOctober 2019July 2021Abandon2100NoNo
16590392LIVER LESION-MOUSE MODELOctober 2019September 2023Allow4730YesNo
16499439NOVEL IMMUNODEFICIENT RAT FOR MODELING HUMAN CANCERSeptember 2019December 2022Abandon3811NoNo
16574685IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACHSeptember 2019October 2022Abandon3711NoNo
16495318Cells and Methods of Uses and Making the SameSeptember 2019February 2023Abandon4121NoNo
16569582Conditional Living SensorsSeptember 2019May 2025Abandon6051NoNo
16567194METHODS FOR GENETIC MODIFICATION OF HEMATOPOIETIC CELLSSeptember 2019March 2024Abandon5441NoNo
16562403METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO VASCULAR BED CELLSSeptember 2019January 2023Abandon4120NoNo
16553235TREATMENT OF HYPERBILIRUBINEMIAAugust 2019November 2024Abandon6041YesNo
16539966DEFINITIVE ENDODERMAugust 2019February 2022Abandon3010NoNo
16536503WIDESPREAD GENE DELIVERY TO MOTOR NEURONS USING PERIPHERAL INJECTION OF AAV VECTORSAugust 2019May 2023Allow4640YesYes
16484768Method for Determining the Effectiveness of Treatment for the Prevention of Heartworm DiseaseAugust 2019April 2024Abandon5641NoNo
16484349METHODS FOR GENERATING MIMETIC INNATE IMMUNE CELLS FROM PLURIPOTENT STEM CELLSAugust 2019May 2025Allow6061YesNo
16534752MOUSE MODEL OF RETINAL DEGENERATIONAugust 2019March 2021Abandon2010NoNo
16483120METHOD FOR PREPARING DENTAL PULP STEM CELLS FROM CELLS DERIVED FROM DENTAL PULP TISSUEAugust 2019July 2021Abandon2401NoNo
16480280CONDITIONALLY IMMORTALIZED CELLS AND METHODS FOR THEIR PREPARATIONJuly 2019August 2022Abandon3701NoNo
16509902IDENTIFICATION, ISOLATION, AND THERAPEUTIC USES OF ENDOTHELIAL STEM CELLS THAT EXPRESS THE ABCG2+ SURFACE MARKERJuly 2019January 2023Abandon4211NoNo
16459236MULTIFUNCTIONAL ALLELESJuly 2019January 2022Allow3021YesNo
16454024CATECHOLAMINE ENZYME FUSIONSJune 2019November 2021Allow2821YesNo
16428906GENETICALLY MODIFIED MOUSE COMPRISING A CHIMERIC TIGITMay 2019May 2022Allow3641YesNo
16464680IL6R BLOCK CAR-T TRANSGENIC VECTOR FOR ALLEVIATING CRS, PREPARATION METHOD THEREOFMay 2019May 2021Allow2321YesNo
16422403MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERSMay 2019June 2023Abandon4941YesNo
16405863METHODS FOR ENHANCING THE PLURIPOTENCY OF STEM CELLSMay 2019July 2021Allow2721YesNo
16387587GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORMApril 2019April 2020Allow1210YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SINGH, ANOOP KUMAR.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
5
(62.5%)
Examiner Reversed
3
(37.5%)
Reversal Percentile
57.5%
Higher than average

What This Means

With a 37.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
166
Allowed After Appeal Filing
25
(15.1%)
Not Allowed After Appeal Filing
141
(84.9%)
Filing Benefit Percentile
15.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SINGH, ANOOP KUMAR - Prosecution Strategy Guide

Executive Summary

Examiner SINGH, ANOOP KUMAR works in Art Unit 1632 and has examined 779 patent applications in our dataset. With an allowance rate of 37.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner SINGH, ANOOP KUMAR's allowance rate of 37.5% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SINGH, ANOOP KUMAR receive 3.12 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SINGH, ANOOP KUMAR is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +68.4% benefit to allowance rate for applications examined by SINGH, ANOOP KUMAR. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 7.5% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.8% of cases where such amendments are filed. This entry rate is in the 34% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 142.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 87% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.1% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 87.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.0% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.